Abstract
Definitive treatment of cancer has eluded scientists for decades. Current therapeutic modalities like surgery, chemotherapy, radiotherapy and receptor-targeted antibodies have varied degree of success and generally have moderate to severe side effects. Gene therapy is one of the novel and promising approaches for therapeutic intervention of cancer. Viral vectors in general and adenoviral (Ad) vectors in particular are efficient natural gene delivery systems and are one of the obvious choices for cancer gene therapy. Clinical and preclinical findings with a wide variety of approaches like tumor suppressor and suicide gene therapy, oncolysis, immunotherapy, anti-angiogenesis and RNA interference using Ad vectors have been quite promising, but there are still many hurdles to overcome. Shortcomings like increased immunogenicity, prevalence of preexisting anti-Ad immunity in human population and lack of specific targeting limit the clinical usefulness of Ad vectors. In recent years, extensive research efforts have been made to overcome these limitations through a variety of approaches including the use of conditionally-replicating Ad and specific targeting of tumor cells. In this review, we discuss the potential strengths and limitations of Ad vectors for cancer therapy.
Current Drug Therapy
Title: Adenoviral Vector-Based Strategies for Cancer Therapy
Volume: 4 Issue: 2
Author(s): Anurag Sharma, Manish Tandon, Dinesh S. Bangari and Suresh K. Mittal
Affiliation:
Abstract: Definitive treatment of cancer has eluded scientists for decades. Current therapeutic modalities like surgery, chemotherapy, radiotherapy and receptor-targeted antibodies have varied degree of success and generally have moderate to severe side effects. Gene therapy is one of the novel and promising approaches for therapeutic intervention of cancer. Viral vectors in general and adenoviral (Ad) vectors in particular are efficient natural gene delivery systems and are one of the obvious choices for cancer gene therapy. Clinical and preclinical findings with a wide variety of approaches like tumor suppressor and suicide gene therapy, oncolysis, immunotherapy, anti-angiogenesis and RNA interference using Ad vectors have been quite promising, but there are still many hurdles to overcome. Shortcomings like increased immunogenicity, prevalence of preexisting anti-Ad immunity in human population and lack of specific targeting limit the clinical usefulness of Ad vectors. In recent years, extensive research efforts have been made to overcome these limitations through a variety of approaches including the use of conditionally-replicating Ad and specific targeting of tumor cells. In this review, we discuss the potential strengths and limitations of Ad vectors for cancer therapy.
Export Options
About this article
Cite this article as:
Sharma Anurag, Tandon Manish, Bangari S. Dinesh and Mittal K. Suresh, Adenoviral Vector-Based Strategies for Cancer Therapy, Current Drug Therapy 2009; 4 (2) . https://dx.doi.org/10.2174/157488509788185123
DOI https://dx.doi.org/10.2174/157488509788185123 |
Print ISSN 1574-8855 |
Publisher Name Bentham Science Publisher |
Online ISSN 2212-3903 |
Call for Papers in Thematic Issues
Novel Therapeutic Approaches and Biomarkers for Chronic Kidney Disease (CKD)
The thematic issue on "Novel Therapeutic Approaches and Biomarkers for CKD" aims to provide a comprehensive exploration of cutting-edge strategies for the management of chronic kidney disease (CKD). This issue will delve into emerging therapeutic targets, focusing on critical aspects such as podocyte injury, endothelial dysfunction, and tubulointerstitial fibrosis, which ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
STAT3: A Potential Drug Target for Tumor and Inflammation
Current Topics in Medicinal Chemistry “Metabolic Aspects” In Inflammatory Bowel Diseases
Current Drug Delivery Glioblastoma Targeted Gene Therapy Based on pEGFP/p53-Loaded Superparamagnetic Iron Oxide Nanoparticles
Current Gene Therapy Anabolic Androgenic Steroids Abuse and Liver Toxicity
Mini-Reviews in Medicinal Chemistry Biomedical Potentialities of Taraxacum officinale-based Nanoparticles Biosynthesized Using Methanolic Leaf Extract
Current Pharmaceutical Biotechnology In Vitro and In Vivo Antimetastatic Effects of ZSTK474 on Prostate Cancer DU145 Cells
Current Cancer Drug Targets 3D-QSAR, Topomer CoMFA, Docking Analysis, and ADMET Predictio n of Thioether Pleuromutilin Derivatives as Antibacterial Agents
Letters in Drug Design & Discovery Treatment Directed to Signalling Molecules in Patients with Advanced Differentiated Thyroid Cancer
Anti-Cancer Agents in Medicinal Chemistry The Development of Pro-Apoptotic Cancer Therapeutics
Mini-Reviews in Medicinal Chemistry Neurokinin-1 Receptor Antagonists as Anticancer Drugs
Letters in Drug Design & Discovery Drugs Interfering with Apoptosis in Breast Cancer
Current Pharmaceutical Design EDITORIAL [Hot Topic: Nuclear Image-Guided Personalized Treatment and Prevention of Cancers]
Current Medicinal Chemistry Design, Synthesis, Crystal Structure and Antitumor Activity of A New Ethyl 3-(quinazolin-4-ylamino)-1H-pyrrole-2-carboxylate Derivative
Letters in Drug Design & Discovery Bispecific Antibodies: An Innovative Arsenal to Hunt, Grab and Destroy Cancer Cells
Current Pharmaceutical Biotechnology Dietary Supplement Therapies for Inflammatory Bowel Disease: Crohn’s Disease and Ulcerative Colitis
Current Pharmaceutical Design The p35 Family of Apoptosis Inhibitors
Current Genomics LncRNA in Tumorigenesis Microenvironment
Current Bioinformatics Thalidomide: A Banned Drug Resurged into Future Anticancer Drug
Current Drug Therapy Targeting Acetyl-CoA Carboxylases: Small Molecular Inhibitors and their Therapeutic Potential
Recent Patents on Anti-Cancer Drug Discovery Computational Identification of microRNA-17-3p in Breast Cancer Cells
MicroRNA